AREN1721: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single AgentAxitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC)Across All Age Groups

Protocol: 
AAAS1990
Phase: 
II

AREN1721: A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single AgentAxitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC)Across All Age Groups

Carcinoma (tRCC). The best treatment for this type of kidney cancer is not
known. This study is looking at 3 different treatment plans and trying to
determine which treatment plan will be best.

Are you Eligible? (Inclusion Criteria)

-Patients must be at least 12 months of age
-Patients may be newly diagnosed or previously received treatment
-Patients must also meet all eligibility criteria as outlined in the study
protocol

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States